Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 6/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.70 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.67 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.67 |
| ▸ | AHCY | P23526 | 1/20 | 0.65 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294015 | 0.95 | PRKACA (0.75) | PRKACAROCK2METTL3METTL14AHCY | |
| SCHEMBL17294035 | 0.95 | PRKACA (0.75) | PRKACAROCK2METTL3METTL14AHCY | |
| SCHEMBL17294023 | 0.95 | PRKACA (0.73) | PRKACAROCK2METTL3METTL14AHCY | |
| SCHEMBL17297714 | 0.95 | PRKACA (0.73) | PRKACAROCK2METTL3METTL14AHCY | |
| SCHEMBL17293999 | 0.95 | PRKACA (0.73) | PRKACAROCK2METTL3METTL14AHCY | |
| SCHEMBL17294024 | 0.93 | PRKACA (0.70) | PRKACAROCK2METTL3METTL14AHCY | |
| SCHEMBL17294000 | 0.92 | PRKACA (0.69) | PRKACAROCK2METTL3METTL14AHCY | |
| SCHEMBL17294012 | 0.89 | ADORA3 (0.69) | PRKACAROCK2METTL3METTL14AHCY | |
| Trifluoromethanesulfonic Acid SCHEMBL17293997 | 0.88 | PRKACA (0.64) | PRKACAROCK2METTL3METTL14HSP90B1 | |
| Trifluoromethanesulfonic Acid SCHEMBL17294018 | 0.88 | PRKACA (0.64) | PRKACAROCK2METTL3METTL14HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107247-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107247-A1 | UBA5 INHIBITORS | UBQLN2, UBTF, UBQLN1 | PRKACA 2626/4885ROCK2 3602/4885METTL3 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.